Evidence map›Paper›PMID 32305094›Full record

Trial reportLancet (London, England)2020

Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign.

Sarah G Staedke, Samuel Gonahasa, Grant Dorsey, Moses R Kamya, Catherine Maiteki-Sebuguzi, Amy Lynd, Agaba Katureebe, Mary Kyohere, Peter Mutungi, Simon P Kigozi and 3 more

Open access · greenAbstract readMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 2 pooled it
21.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Bioefficacy and durability of OlysetInfectious diseases of poverty · 2021
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Sarah G StaedkeDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Infectious Diseases Research Collaboration, Kampala, Uganda. Electronic address: sarah.staedke@lshtm.ac.uk.
Samuel GonahasaInfectious Diseases Research Collaboration, Kampala, Uganda.
Grant DorseyDepartment of Medicine, University of California, San Francisco, CA, USA.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda; Department of Medicine, Makerere University, Kampala, Uganda.
Catherine Maiteki-SebuguziInfectious Diseases Research Collaboration, Kampala, Uganda.
Amy LyndDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK.
Agaba KatureebeInfectious Diseases Research Collaboration, Kampala, Uganda.
Mary KyohereInfectious Diseases Research Collaboration, Kampala, Uganda.
Peter MutungiInfectious Diseases Research Collaboration, Kampala, Uganda.
Simon P KigoziInfectious Diseases Research Collaboration, Kampala, Uganda.
Jimmy OpigoNational Malaria Control Division, Ministry of Health, Kampala, Uganda.
Janet HemingwayDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK.
Martin J DonnellyDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK; Wellcome Sanger Institute, Hinxton, UK.
Infectious Diseases Research Collaboration · UGLiverpool School of Tropical Medicine · GBLondon School of Hygiene & Tropical Medicine · GBMinistry of Health · UGUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-lasting insecticidal nets (LLINs) are the primary malaria prevention tool, but their effectiveness is threatened by pyrethroid resistance. We embedded a pragmatic cluster-randomised trial into Uganda's national LLIN campaign to compare conventional LLINs with those containing piperonyl butoxide (PBO), a synergist that can partially restore pyrethroid susceptibility in mosquito vectors.

methods104 health sub-districts, from 48 districts in Uganda, were randomly assigned to LLINs with PBO (PermaNet 3.0 and Olyset Plus) and conventional LLINs (PermaNet 2.0 and Olyset Net) by proportionate randomisation using an iterative process. At baseline 6, 12, and 18 months after LLIN distribution, cross-sectional surveys were done in 50 randomly selected households per cluster (5200 per survey); a subset of ten households per cluster (1040 per survey) were randomly selected for entomological surveys. The primary outcome was parasite prevalence by microscopy in children aged 2-10 years, assessed in the as-treated population at 6, 12, and 18 months. This trial is registered with ISRCTN, ISRCTN17516395.

findingsLLINs were delivered to households from March 25, 2017, to March 18, 2018, 32 clusters were randomly assigned to PermaNet 3.0, 20 to Olyset Plus, 37 to PermaNet 2.0, and 15 to Olyset Net. In the as-treated analysis, three clusters were excluded because no dominant LLIN was received, and four clusters were reassigned, resulting in 49 PBO LLIN clusters (31 received PermaNet 3.0 and 18 received Olyset Plus) and 52 non-PBO LLIN clusters (39 received PermaNet 2.0 and 13 received Olyset Net). At 6 months, parasite prevalence was 11% (386/3614) in the PBO group compared with 15% (556/3844) in the non-PBO group (prevalence ratio [PR] adjusted for baseline values 0·74, 95% CI 0·62-0·87; p=0·0003). Parasite prevalence was similar at month 12 (11% vs 13%; PR 0·73, 95% CI 0·63-0·85; p=0·0001) and month 18 (12% vs 14%; PR 0·84, 95% CI 0·72-0·98; p=0·029).

interpretationIn Uganda, where pyrethroid resistance is high, PBO LLINs reduced parasite prevalence more effectively than did conventional LLINs for up to 18 months. This study provides evidence needed to support WHO's final recommendation on use of PBO LLINs.

fundingThe Against Malaria Foundation, UK Department for International Development, Innovative Vector Control Consortium, and Bill and Melinda Gates Foundation.

Indexed as

AnimalsAnophelesChildChild, PreschoolCross-Sectional StudiesFemaleHumansInsecticide ResistanceInsecticide-Treated BednetsMalariaMaleMosquito VectorsPesticide SynergistsPiperonyl ButoxideUgandaPesticide SynergistsPiperonyl Butoxide

Identifiers

PMID32305094
PMCPMC7181182
OpenAlexW3016380391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.